
UK and US-based cell therapy company Adaptimmune has made two new appointments to its board. Dr Jonathan Knowles joins as …

Roche has opened a new manufacturing facility at its campus in Nutley, New Jersey, that will supply dosage forms for …
Merck & Co has fallen foul of US regulations on environmental controls at two manufacturing plants and agreed to pay …

A new NHS-backed social network has launched to provide support to patients with long-term conditions through ‘personal health planning’. How …
Our round-up of pharma manufacturing news sees a green energy drive from GSK, facility updates from Stirling Pharma, Reckitt Benckiser …

Takeda Pharmaceutical Company has completed its acquisition of Nycomed and named Frank Morich as chief executive of the Zurich-based firm. …
AstraZeneca’s lung cancer drug selumetinib has failed to hit its primary endpoint in a Phase II trial. The trial compared …
SHL Group is honored to have recently received certification for the Good Design Award for its revolutionary auto injector, Molly. …
Jean-Pierre Garnier has been elected chairman of Swiss biopharmaceutical company Actelion. He has sat on the company’s board since May …
Chinese active ingredient manufacturer Sichuan Pharmaceutical has been sent a warning by the US FDA for failing to sort out …

Janssen was once again the standout winner at last night’s PM Society’s Digital Media Awards. The pharma company beat its …

NICE has rejected GSK’s new lupus treatment Benlysta in draft guidance.Co-developed with biotech company HGS, the drug has been hailed …
Mr. Barry Simms, Chiltern’s Country Manager, North America, commented, “Chiltern continues to look for opportunities to increase our strategic footprint …
Astellas Pharma has abandoned the development of its oral direct factor Xa inhibitor darexaban. The Japanese firm blamed both the …
NICE has not recommended Sanofi’s prostate cancer drug Jevtana due to its high cost and concerns over its safety data. …
The globalisation of pharmaceutical research and development is creating a wave of job opportunities in emerging markets such as India …

Merck & Co has exited a joint venture with J&J, selling its stake in the J&J/Merck Consumer Pharmaceuticals business to …
NICE has blamed the pharma industry’s ‘inefficient’ and increasingly costly R&D model for the rising price of cancer drugs. NICE …

Novartis has launched its orphan drug Votubia in the UK for patients with a rare type of brain tumour. Votubia …
Clinical Commissioning Groups are concerned by the amount of bureaucracy they face and feel they don’t have enough support, according …